Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
LENZ Therapeutics, Inc. (LENZ)
NASDAQHealth CareBiotechnologySnapshot 2026-10-23
$3.16-2.77%
Close 2026-10-23 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|---|---|
| Quarter ending 2026-12-30 | ||
| Revenue | — | 4.46M |
| EPS | — | -0.794 |
| Annual ending 2026-12-31 | ||
| Revenue | — | 16.01M |
| EPS | — | -4.08 |
| Annual ending 2027-12-31 | ||
| Revenue | — | 37.55M |
| EPS | — | |
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Operating losses improve from negative $44.1 million in Q1 2026 | A primary condition in LENZ Therapeutics, Inc.'s published investment case. The stated target is Operating income improves toward less negative than -44.1 USD_MILLIONS. | Broken | Operating losses worsen beyond negative $44.1 million | Operating income: $-34.172M FY2026-Q2; GAAP. Published target: Operating income improves toward less negative than -44.1 USD_MILLIONS. Target period is not explicitly aligned with this observation. Source published Aug 11, 2026-34,172,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: a39c1cb8-1f0b-4f2c-8b98-f028827c849b. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Oct 29, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business in an early product-launch phase, not an established compounder. The thesis is on watch: revenue and partnerships are progressing, while recent results have been weak and the company remains loss-making.
The valuation evidence is mixed: LENZ is described as cheap versus peers, but the model has low confidence and shows a negative expectations gap. The priced-in signal is tagged justified, with low fragility, so the evidence does not point to a clear mismatch between expectations and the business outlook.
Near term, launch execution is supporting revenue growth, while management has made only limited progress in reducing operating losses amid launch spending. Global filings and licensing work are advancing, but recent earnings misses and a 51% estimated chance of a miss on the next print make results a key risk.
The multi-year thesis depends on product adoption continuing to lift revenue and on partnerships translating into broader commercialization. Near term, a guidance cut or further weak results would add pressure; continued strength among healthcare sector bellwethers could support sector momentum, though that would not resolve LENZ’s company-specific execution risks.
Over the next 1 to 3 years, LENZ has early signs of commercial progress, but the long-term thesis remains unproven because losses persist and recent financial performance trails its industry cohort. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management figures unavailable.
Source status: eligible.
Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stated in 2 of last 2 quarters. Net loss improved from $41.5 million in 2026-Q1 to $31.9 million in 2026-Q2, with SG&A expenses decreasing from $45.0 million to $39.4 million. Management continues to invest in launch while managing operating losses. The trajectory shows limited progress in reducing losses amid launch investments.
Delivery assessment Oct 24, 2026Successful product launches including telehealth services | Telehealth launch supports revenue growth. | Improving | No new product launches or telehealth expansion fails | VIZZ scripts +45% MoM vs qualitative launch target VIZZ scripts up 45% MoM; telehealth and national TV push launched; analyst reiterated Buy. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 of last 2 quarters. Revenue increased from $1.9 million in 2026-Q1 to $5.5 million in 2026-Q2, driven by product sales and license revenue growth. Management emphasized expanding sales force, telehealth launch, and DTC campaigns to drive adoption. The trajectory is delivering with accelerating revenue and patient engagement. Delivery assessment Oct 24, 2026 |
Revenue reaches about $1.9 million in Q3 2026 | A primary condition in LENZ Therapeutics, Inc.'s published investment case. The stated target is >=1.9 USD_MILLIONS. | Improving | Revenue falls below $1.6 million in Q3 2026 | Revenue: $5.486M FY2026-Q2; GAAP. Published target: >=1.9 USD_MILLIONS. Target period ends 2026-09-30; this observation covers 2026-Q2. Source published Aug 11, 20265,486,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: a39c1cb8-1f0b-4f2c-8b98-f028827c849b. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 of last 2 quarters. Revenue increased from $1.9 million in 2026-Q1 to $5.5 million in 2026-Q2, driven by product sales and license revenue growth. Management emphasized expanding sales force, telehealth launch, and DTC campaigns to drive adoption. The trajectory is delivering with accelerating revenue and patient engagement. Delivery assessment Oct 24, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.51 → $-2.38 · observed estimates
$0.06B → $0.04B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-07-25 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-07-26 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-07-27 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-07-28 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-07-29 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-07-30 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-07-31 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-08-01 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-02 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-08-03 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-08-04 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-08-05 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-06 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-07 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-08 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-08-09 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-10 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-08-12 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-13 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-14 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-15 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-16 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-17 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-18 | $-3.42 | $63,174,043 | 5 / 5 |
| 2026-08-19 | $-3.42 | $63,174,043 | 5 / 5 |
| 2026-08-20 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-21 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-22 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-23 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-24 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-25 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-26 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-27 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-28 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-29 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-30 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-31 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-01 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-02 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-03 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-04 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-05 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-06 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-07 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-08 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-09 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-10 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-11 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-12 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-13 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-14 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-15 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-16 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-17 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-18 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-19 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-20 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-21 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-22 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-23 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-24 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-25 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-26 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-27 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-28 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-29 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-30 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-01 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-02 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-03 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-04 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-05 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-06 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-07 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-08 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-09 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-10 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-11 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-12 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-13 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-14 | $-2.58 | $42,851,129 | 5 / 5 |
| 2026-10-15 | $-2.58 | $42,851,129 | 5 / 5 |
| 2026-10-16 | $-2.58 | $42,851,129 | 5 / 5 |
| 2026-10-17 | $-2.58 | $42,851,129 | 5 / 5 |
| 2026-10-18 | $-2.58 | $42,851,129 | 5 / 5 |
| 2026-10-19 | $-2.58 | $42,851,129 | 5 / 5 |
| 2026-10-20 | $-2.56 | $41,836,843 | 5 / 5 |
| 2026-10-21 | $-2.56 | $41,836,843 | 5 / 5 |
| 2026-10-22 | $-2.38 | $37,551,129 | 5 / 5 |
| 2026-10-23 | $-2.38 | $37,551,129 | 5 / 5 |
| 2026-10-24 | $-2.38 | $37,551,129 | 5 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Sep 25–Oct 24 · 2 recorded
0 raises · 1 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.